Qiliqiangxin attenuates isoproterenol-induced cardiac remodeling in mice.

about

Qiliqiangxin attenuates isoproterenol-induced cardiac remodeling in mice.

Item

http://www.wikidata.org/entity/Q49413287

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Qiliqiangxin attenuates isoproterenol-induced cardiac remodeling in mice.

@en

Qiliqiangxin attenuates isoproterenol-induced cardiac remodeling in mice.

@nl

type

Item

label

Qiliqiangxin attenuates isoproterenol-induced cardiac remodeling in mice.

@en

Qiliqiangxin attenuates isoproterenol-induced cardiac remodeling in mice.

@nl

prefLabel

Qiliqiangxin attenuates isoproterenol-induced cardiac remodeling in mice.

@en

Qiliqiangxin attenuates isoproterenol-induced cardiac remodeling in mice.

@nl

P1476

Qiliqiangxin attenuates isoproterenol-induced cardiac remodeling in mice.

@en

P2093

Haifeng Zhang

http://www.w3.org/2001/XMLSchema#string

Hui Wang

http://www.w3.org/2001/XMLSchema#string

Jialiang Zhang

http://www.w3.org/2001/XMLSchema#string

Mengyuan Huang

http://www.w3.org/2001/XMLSchema#string

Ping Lv

http://www.w3.org/2001/XMLSchema#string

Shutong Shen

http://www.w3.org/2001/XMLSchema#string

Xiaodong Wu

http://www.w3.org/2001/XMLSchema#string

Xiaoting Wu

http://www.w3.org/2001/XMLSchema#string

Xinli Li

http://www.w3.org/2001/XMLSchema#string

P2860

The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction

Traditional Chinese Medication Qiliqiangxin attenuates cardiac remodeling after acute myocardial infarction in mice.

The fibrosis-cell death axis in heart failure

Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.

Peroxisome proliferator-activated receptor-γ activation prevents sepsis-related cardiac dysfunction and mortality in mice.

Rosiglitazone inhibits hypercholesterolaemia-induced myeloperoxidase upregulation--a novel mechanism for the cardioprotective effects of PPAR agonists.

PPARγ signaling and metabolism: the good, the bad and the future.

PPARγ and Its Role in Cardiovascular Diseases.

Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation.

New targets to treat the structural remodeling of the myocardium.

P304

5585-5593

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29312510

http://www.w3.org/2001/XMLSchema#string

P932

5752908

http://www.w3.org/2001/XMLSchema#string